Advertisement
Canada markets open in 2 hours 47 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7307
    -0.0014 (-0.19%)
     

  • CRUDE OIL

    82.94
    -0.42 (-0.50%)
     

  • Bitcoin CAD

    90,874.27
    +147.21 (+0.16%)
     

  • CMC Crypto 200

    1,433.47
    +9.37 (+0.66%)
     

  • GOLD FUTURES

    2,330.20
    -11.90 (-0.51%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,708.75
    +102.00 (+0.58%)
     

  • VOLATILITY

    15.82
    +0.13 (+0.83%)
     

  • FTSE

    8,087.72
    +42.91 (+0.53%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6834
    -0.0002 (-0.03%)
     

Lilly (LLY) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·3 min read

For the quarter ended December 2022, Eli Lilly (LLY) reported revenue of $7.3 billion, down 8.7% over the same period last year. EPS came in at $2.09, compared to $2.49 in the year-ago quarter.

The reported revenue represents a surprise of -0.28% over the Zacks Consensus Estimate of $7.32 billion. With the consensus EPS estimate being $1.83, the EPS surprise was +14.21%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net sales-Basaglar (LY2963016 / Insulin Glargine) - ROW: $70.90 million versus the four-analyst average estimate of $74.47 million. The reported number represents a year-over-year change of -8.4%.

  • Revenue -Other Neuroscience- Outside U.S. $15.20 million versus the four-analyst average estimate of $32.44 million.

  • Net sales-Cyramza (Ramucirumab /IMC-1121B) - ROW: $185.70 million compared to the $158.27 million average estimate based on four analysts. The reported number represents a change of +4% year over year.

  • Net sales-Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) - US: $1.53 billion versus $1.61 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.4% change.

  • Basaglar (LY2963016 / Insulin Glargine) - Total: $201.70 million versus $205.41 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -16.8% change.

  • Cyramza (Ramucirumab /IMC-1121B) -Total: $277.80 million compared to the $249.10 million average estimate based on four analysts. The reported number represents a change of +2.7% year over year.

  • Revenue - Diabetes - Other: $27.90 million versus the four-analyst average estimate of $142.34 million.

  • Trulicity (Dulaglutide / GLP-1 Fc / LY2189265) -Total: $1.94 billion compared to the $2.08 billion average estimate based on four analysts. The reported number represents a change of +2.8% year over year.

  • Jardiance (Empagliflozin/BI 10773)- Total: $612.30 million compared to the $610.59 million average estimate based on four analysts. The reported number represents a change of +41.8% year over year.

  • Net sales- Immunology: $933.60 million versus $943.70 million estimated by four analysts on average.

  • Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor - Total: $205.80 million versus the four-analyst average estimate of $197.21 million. The reported number represents a year-over-year change of -32.8%.

  • Net sales-Taltz (Ixekizumab / LY2439821 / IL-17) - Total: $707.80 million compared to the $743.25 million average estimate based on four analysts. The reported number represents a change of +9.3% year over year.

View all Key Company Metrics for Lilly here>>>

Shares of Lilly have returned -5.7% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research